Ads
related to: genetic testing for prostate cancer- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Genomic Testing
Read How Testing Could
Help Inform Your Treatment Plan.
- Oral Medication
Learn More About An Oral Treatment
For Metastatic Prostate Cancer.
- Real Patient Story
Learn How A Patient's BRCA Status
Informed His Treatment Journey.
- Clinical Study Data
Find Clinical Study Data
At The Patient Site.
- Patient Support Program
Learn About A Treatment Option
And Patient Support.
- Side Effect Information
- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
Search results
Results From The WOW.Com Content Network
The analysis showed that both genetic and lifestyle factors increased the risk of death from prostate cancer. Death before 75 was considered an early death, and deaths after 75 were deemed late.
A prostate cancer biomarker test that utilizes 17 genetic markers has demonstrated a high degree of accuracy in screening for serious cancer. The test also significantly reduced unnecessary ...
Prostate cancer in BRCA mutation carriers tends to appear a decade earlier than normal, and it tends to be more aggressive than normal. As a result, annual prostate screening, including a digital rectal examination, is appropriate at age 40 among known carriers, rather than age 50. [9]: Ch8 Cancer of the pancreas tends to run in families, even ...
n/a Ensembl ENSG00000225937 n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) Chr 9: 76.69 – 76.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer ...
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Currently, only five cancers have standard screening tests: breast, colorectal, cervical, lung and prostate. The majority of cancers don’t have one, which means MCED tests have the potential to ...